Corneal Disease Clinical Trial
Official title:
Cornea Donor Study: The Effect of Donor Age on Penetrating Keratoplasty for Endothelial Disease
The Cornea Donor Study (CDS) was designed as a prospective cohort study with the following
objectives:
To determine whether the graft-failure rate over a 5-year follow-up period following corneal
transplantation is the same when using corneal tissue from donors older than 65 years of age
compared with tissue from younger donors.
To assess the relationship between donor/recipient ABO blood type compatibility and graft
failure due to rejection.
To assess corneal endothelial cell density as an indicator of the health of the cornea and as
a alternate outcome measure (in an optional Specular Microscopy Ancillary Study).
The study enrolled 1101 subjects with a corneal disease considered to be at moderate risk for
failure (principally Fuchs' dystrophy and pseudophakic corneal edema). A donor cornea meeting
the following criteria was assigned to the subject by one of 43 participating eye banks:
- donor age 10 to 75 years
- endothelial cell count 2300 to 3300
- tissue quality very good to excellent
- death to preservation time <12 hrs if body refrigerated or eyes on ice and <8 hrs if not
- death to surgery time <5 days
The cornea surgeon (investigator) and patient were masked to donor age and characteristics of
the donor cornea. Preoperative management, surgical technique, and postoperative care,
including prescription of medications, were provided according to each investigator's
customary routine. The follow-up visit schedule for the initial six months was left to each
investigator's discretion and after this time the minimum follow-up visit schedule included a
visit between six and 12 months and then one visit every 12 months through five years. The
primary study outcome was graft survival at five years. The definition of graft failure,
based on the definition used in Collaborative Corneal Transplantation Studies, was a regraft
or, in the absence of regraft, a cloudy cornea in which there was loss of central graft
clarity sufficient to compromise vision for a minimum of three consecutive months. Follow-up
in the initial phase of the study continued for five years unless the patient had a regraft
of the study eye.
For the ABO compatibility study, the ABO blood type of both the donor and recipient were
determined in order to compare the rate of graft failure for ABO-compatible cases with the
rate for ABO-incompatible cases.
For the Specular Microscopy Ancillary Study, endothelial cell counts were determined from
specular images by a central reading center, and the relationship of the cell counts to donor
age were assessed. In the initial phase of the study, specular images were obtained at 6
months, and then annually through five years post-transplant.
Five-year follow up was completed in November 2007. The 5-year cumulative probability of
success was 86%: 86% in the <66.0 year donor age group and 86% in the >=66.0 year donor age
group (difference = 0%, upper limit of one-sided 95% confidence interval = 4%). Adjusting for
baseline endothelial cell density had no appreciable effect on these results. In a
statistical model with donor age as a continuous variable, there was not a significant
relationship between donor age and outcome (P=0.11). Three graft failures were due to primary
donor failure, 8 to uncorrectable refractive error, 48 to graft rejection, 46 to endothelial
decompensation, and 30 to other causes. At least one probable or definite graft rejection
episode preceded graft failure in 23 of the 46 failures attributed to endothelial
decompensation (4 definite and 19 probable) and in 18 of the 30 failures attributed to other
causes (4 definite and 14 probable). The distribution of causes of failure between the donor
age groups did not substantially differ.
Although the 5-year results indicated no difference in the success rate of moderate-risk
transplants according to donor age, results from the SMAS indicated that among the successful
cases, there was a slight association between donor age and endothelial cell loss, with the
cell loss after 5 years being slightly lower in corneas from younger donors (r adjusted for
baseline endothelial cell density = -0.19, 95% confidence interval -0.29 to -0.08). Whether
this slight association between cell loss and donor age is of clinical importance is not
known. Of perhaps even greater importance, however, was the finding that irrespective of
donor age, endothelial cell loss was substantial over the first five years after transplant
even when the graft had been successful. Half of the successful cases experienced a cell loss
of 70% or more, and at five years more than half had an endothelial cell density <800
cells/mm2.
Patients in the CDS continued in annual follow up through 2012 in order to to determine the
overall 10-year survival rate for moderate risk grafts and to determine whether the
graft-failure rate is related to donor age. Additional objectives included determining the
value of endothelial cell density in predicting graft failure and evaluating donor and
recipient characteristics that may be predictive of late graft failure. All CDS subjects who
were active at the 5-year exam were eligible for the extended follow-up phase.
As part of the Specular Microscopy Ancillary Study, follow-up images were obtained during the
extended follow-up phase at 7-8 years and again at 10-years. The same procedures used during
the first 5 years were followed for the grading of the 7-8 year and 10-year images.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05114928 -
Correlation Between Q-value Changes and Progression of Pediatric Keratoconus.
|
||
Recruiting |
NCT06160960 -
Influence of Pupillary Behavior During Eye Surgery on Morphological and Functional Outcome
|
||
Completed |
NCT00357435 -
Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases
|
||
Completed |
NCT04484402 -
Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05581875 -
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
|
Phase 1/Phase 2 | |
Recruiting |
NCT06101017 -
Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and Disease
|
||
Withdrawn |
NCT03421548 -
Implantable Intraocular Pressure Sensor for Glaucoma Monitoring in Patients With Boston Keratoprosthesis Type 1
|
N/A | |
Withdrawn |
NCT05700864 -
NGF Treatment for Patients With Neuropathic Corneal Pain
|
Phase 1 | |
Enrolling by invitation |
NCT05758753 -
QST for Corneal Nerve Function
|
N/A | |
Terminated |
NCT00001310 -
Tissue Studies of Human Eye Diseases
|
||
Completed |
NCT02386774 -
Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa
|
N/A | |
Recruiting |
NCT05694247 -
Study to Evaluate the Clinical Safety and Performance of the CorNeat KPro for Treatment of Corneal Blindness
|
N/A | |
Not yet recruiting |
NCT06294015 -
Efficacy of 20% Autologous Serum Drops in the Treatment of Corneal Epitheliopathy Associated With Antihypertensive Glaucoma Drops.
|
Phase 4 | |
Completed |
NCT00654888 -
Automated Lamellar Keratectomy in Symptomatic Patients With Bullous Keratopathy
|
N/A | |
Recruiting |
NCT04251143 -
Dresden Corneal Disease and Treatment Study
|
||
Withdrawn |
NCT02374723 -
Evaluation of Biosynthetic Constructs to Replace Donor Corneas
|
Phase 1 | |
Completed |
NCT01384487 -
Nidek RS3000 Comparative Study
|
N/A | |
Completed |
NCT00804505 -
Hybrid SA RGP Center/S-H Skirt Daily Wear 90 Day Multicenter Study
|
N/A | |
Completed |
NCT04475900 -
Computer-aided Diagnosis of Ocular Diseases Based on Corneal Biomechanics
|
||
Recruiting |
NCT05573802 -
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
|
Phase 1/Phase 2 |